| Institution | Analyst | Contact | Recomendation | Target Price | Last Revision |
|---|---|---|---|---|---|
| Itaú | Marcelo Sá | marcelo.a-sa@itaubba.com | Outperform | R$ 50.10 | 05/08/2024 |
| BTG Pactual | Antonio Junqueira | antonio.junqueira@btgpactual.com | Buy | R$ 48.00 | 10/30/2024 |
| XP Investimentos | Vladimir Pinto | vladimir.pinto@xpi.com.br | Buy | R$ 46,00 | 08/27/2024 |
| Citibank | João Pimentel | joao.pimentel@citi.com | Buy | R$ 45,00 | 09/12/2024 |
| UBS | Giuliano Ajeje | giuliano.ajeje@ubs.com | Buy | R$ 44.00 | 11/18/2024 |
| Santander | André Sampaio | ansampaio@santander.com.br | Buy | R$ 43,38 | 02/08/2024 |
| JP Morgan | Arthur Pereira | arthur.pereira@jpmchase.com | Hold | R$ 42.00 | 03/10/2025 |
| Scotiabank | Renato Pinto | renato.pinto@scotiabank.com | Outperform | R$ 41,00 | 08/02/2025 |
| Bradesco | Francisco Navarrete | francisco.navarrete@bradescobbi.com.br | Outperform | R$ 41.00 | 01/09/2025 |
| BofA Merrill Lynch | Gustavo Faria | gustavo.faria@bofa.com | Buy | R$ 41,00 | 08/13/2024 |
| Goldman Sachs | Bruno Amorim | bruno.amorim@gs.com | Buy | R$ 40,50 | 15/01/2025 |
| Morgan Stanley | Fernando Amaral | Fernando.Amaral@morganstanley.com | Overweight | R$ 40.00 | 01/20/2025 |
| Safra | Carolina Carneiro | carolina.carneiro@safra.com.br | Outperform | R$ 40.00 | 27/03/2025 |
| HSBC | Lilyanna Yang | lilyanna.yang@us.hsbc.com | Buy | R$ 34.00 | 01/09/2025 |
| Average | R$ 42.57 | ||||
| Minimal | R$ 37.54 | ||||
| Maximum | R$ 50.10 |
Equatorial is covered by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding Equatorial´s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Equatorial or its management. Equatorial does not, by its reference above or distribution, imply its endorsement of or concurrence with such information, conclusions or recommendations. Equatorial does not warrant that the above list of analysts is complete nor updated, and the information herein provided are subject to the authorization of the analysts.